ITGAM and Miyoshi myopathy: The combination of these two parameters (i.e., preferential localization of VISTA+, CD11b cells in tumor multiplied by preferential localization of CD8 T-cells in stroma,), however, the parameter we termed VISTA-associated T-cell exclusion clearly divided MM patients with low versus high OS (Figure 6E, [HR: 16.60; 95% CI: 4.54–62.50; p < 0.0001]).